Clinical Analysis of Glioma: Anaplastic Astrocytoma and Glioblastoma

  • J. Shingai
  • M. Kanno


There have been many reports on the effects of radiotherapy and chemotherapy and on the factors influencing the prognosis of malignant gliomas [1, 3, 5, 6, 10–12, 15, 17, 18]. The approach of most early investigations was historical [e.g., 3, 17, 18], but in recent years the number of randomized studies reporting on the effects of radiotherapy or chemotherapy has increased [1, 5, 10–12]. Among such studies, some have acknowledged the effectiveness of adjuvant chemotherapy [1, 3, 10, 15, 18], but others report negative findings in this regard [5, 12, 17]. In contrast, there has been some uniformity of opinion concerning the effectiveness of radiotherapy [2, 3, 13, 16, 18, 19]. Among such studies, however, many have reported the effects of adjuvant therapy for a group in which glioblastoma and other anaplastic gliomas were discussed together as a single disease entity [1, 3, 5, 12, 17, 18].


Malignant Glioma Total Resection Anaplastic Astrocytoma Glioblastoma Patient Anaplastic Glioma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Afra D, Kocsis B, Dobay J, Eckhardt S (1983) Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in the postoperative treatment of malignant gliomas. J Neurosurg 59: 106–110PubMedCrossRefGoogle Scholar
  2. 2.
    Bouchard J, Peirce CB (1960) Radiation therapy in the management of neoplasms of the central nervous system, with a special note in regard to children; twenty years’ experience, 1939–1958. Am J Roentogenol 84: 610–627Google Scholar
  3. 3.
    Chin HW, Young AB, Maruyama Y (1981) Survival response of malignant gliomas to radiotherapy with or without BCNU or methyl-CCNU chemotherapy at the University of Kentucky Medical Center. Cancer Treat Rep 65: 45–51PubMedGoogle Scholar
  4. 4.
    Cox DR (1972) Regression model and life tables. JR Stat Soc (B) 34: 187–200Google Scholar
  5. 5.
    European Organization for Research on Treatment of Cancer(EORTC), Brain Tumor Group (1981) Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supra-tentorial brain gliomas. J Neurosurg 55: 27–31CrossRefGoogle Scholar
  6. 6.
    Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E, Batzdorf U, Brooks WH, Hunt WE, Mealey J, Odom GL, Paoletti P, Ransohoff J, Robertson JT, Selker PG, Shapiro WR, Smith KR, Wilson CB, Strike TA (1983) Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as addition to surgery and radiotherapy for the treatment of malignant gliomas. Cancer Treat Rep 67: 121–132PubMedGoogle Scholar
  7. 7.
    Hoshino T, Wilson CB (1975) Review of basic concepts of cell kinetics as applied to brain tumors. J Neurosurg 42: 123–131PubMedCrossRefGoogle Scholar
  8. 8.
    Hoshino T, Wilson CB, Rosenblum ML, Barker M (1975) Chemotherapeutic implications of growth fraction and cell cycle time in glioblastomas. J Neurosurg 43: 127–135PubMedCrossRefGoogle Scholar
  9. 9.
    Kaplan EL, Meier P (1958) Nonparametric estimation for incomplete observations. J Am Stat Assoc 53: 457–481CrossRefGoogle Scholar
  10. 10.
    Levin VA, Wilson CB, Davis R, Wara WM, Pisher TL, Irwin L (1979) A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for the treatment of primary malignant gliomas. J Neurosurg 51: 526–532PubMedCrossRefGoogle Scholar
  11. 11.
    Levin VA, Wara WM, Davis RL, Vestnys P, Resser KJ, Vatsko K, Nutik S, Gutin PH, Wilson CB (1985) Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg 63: 218–233PubMedCrossRefGoogle Scholar
  12. 12.
    Nelson DF, Shoenfeld D, Weinstein AS, Nelson JS, Wasserman T, Goodman RL, Carabell S (1983) A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of and RTOG study. Int J Rad Oncol Biol Phys 9: 1143–1151CrossRefGoogle Scholar
  13. 13.
    Poisson M, Pouillart P, Bataini JP, Mashaly R, Pertuiset BF, Metzger J (1979) Malignant gliomas treated after surgery by combination chemotherapy and delayed radiation; I. Analysis of results. Acta Neurochirurgica 51: 15–25PubMedCrossRefGoogle Scholar
  14. 14.
    Roth JG, Elvidge AR (1960) Glioblastoma multiforme: A clinical survey. J Neurosurg 17:736–750PubMedCrossRefGoogle Scholar
  15. 15.
    Scott GM, Gilbert FB (1980) Epilepsy and other factors in the prognosis of gliomas. Acta Neurol Scandinav 61: 227–239CrossRefGoogle Scholar
  16. 16.
    Seiler RW, Greiner RH, Zimmerman A, Markwalder H (1978) Radiotherapy combined with procarbazine, bleomycin, and CCNU in the treatment of high-grade supratentorial astrocytomas. J Neurosurg 48: 861–865PubMedCrossRefGoogle Scholar
  17. 17.
    Stage WS, Stein JJ (1974) Treatment of malignant astrocytomas. Am J Roentogenol 120:7–18Google Scholar
  18. 18.
    Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealer J Jr, Norrell HA, Qwens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49: 333–343PubMedCrossRefGoogle Scholar
  19. 19.
    Weir B, MSc, Frcs(C) (1973) The relative significance of factors affecting postoperative survival in astrocytomas, grade 3 and 4. J Neurosurg 38: 448–452PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1988

Authors and Affiliations

  • J. Shingai
  • M. Kanno

There are no affiliations available

Personalised recommendations